FRTX
Price
$0.75
Change
-$0.00 (-0.00%)
Updated
Dec 17 closing price
70 days until earnings call
LXRX
Price
$0.68
Change
-$0.05 (-6.85%)
Updated
Dec 18, 04:59 PM (EDT)
84 days until earnings call
Ad is loading...

FRTX vs LXRX

Header iconFRTX vs LXRX Comparison
Open Charts FRTX vs LXRXBanner chart's image
Fresh Tracks Therapeutics
Price$0.75
Change-$0.00 (-0.00%)
Volume$11.62K
CapitalizationN/A
Lexicon Pharmaceuticals
Price$0.68
Change-$0.05 (-6.85%)
Volume$79.04K
CapitalizationN/A
FRTX vs LXRX Comparison Chart
Loading...
FRTX
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
LXRX
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
FRTX vs. LXRX commentary
Dec 19, 2024

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is FRTX is a StrongBuy and LXRX is a Hold.

COMPARISON
Comparison
Dec 19, 2024
Stock price -- (FRTX: $0.75 vs. LXRX: $0.73)
Brand notoriety: FRTX and LXRX are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: FRTX: 515% vs. LXRX: 127%
Market capitalization -- FRTX: $4.48M vs. LXRX: $265.41M
FRTX [@Biotechnology] is valued at $4.48M. LXRX’s [@Biotechnology] market capitalization is $265.41M. The market cap for tickers in the [@Biotechnology] industry ranges from $486.73B to $0. The average market capitalization across the [@Biotechnology] industry is $2.67B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

FRTX’s FA Score shows that 1 FA rating(s) are green whileLXRX’s FA Score has 1 green FA rating(s).

  • FRTX’s FA Score: 1 green, 4 red.
  • LXRX’s FA Score: 1 green, 4 red.
According to our system of comparison, both FRTX and LXRX are a bad buy in the long-term.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

FRTX’s TA Score shows that 6 TA indicator(s) are bullish while LXRX’s TA Score has 5 bullish TA indicator(s).

  • FRTX’s TA Score: 6 bullish, 3 bearish.
  • LXRX’s TA Score: 5 bullish, 2 bearish.
According to our system of comparison, both FRTX and LXRX are a good buy in the short-term.

Price Growth

FRTX (@Biotechnology) experienced а 0.00% price change this week, while LXRX (@Biotechnology) price change was +0.31% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was -6.67%. For the same industry, the average monthly price growth was -1.92%, and the average quarterly price growth was +0.65%.

Reported Earning Dates

FRTX is expected to report earnings on Feb 26, 2025.

LXRX is expected to report earnings on Mar 12, 2025.

Industries' Descriptions

@Biotechnology (-6.67% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
LXRX($265M) has a higher market cap than FRTX($4.48M). FRTX YTD gains are higher at: -14.685 vs. LXRX (-52.013). FRTX has higher annual earnings (EBITDA): -5.65M vs. LXRX (-198.7M). LXRX has more cash in the bank: 258M vs. FRTX (251K). FRTX has less debt than LXRX: FRTX (0) vs LXRX (101M). FRTX has higher revenues than LXRX: FRTX (8.01M) vs LXRX (5.23M).
FRTXLXRXFRTX / LXRX
Capitalization4.48M265M2%
EBITDA-5.65M-198.7M3%
Gain YTD-14.685-52.01328%
P/E RatioN/AN/A-
Revenue8.01M5.23M153%
Total Cash251K258M0%
Total Debt0101M-
FUNDAMENTALS RATINGS
FRTX vs LXRX: Fundamental Ratings
FRTX
LXRX
OUTLOOK RATING
1..100
3553
VALUATION
overvalued / fair valued / undervalued
1..100
11
Undervalued
59
Fair valued
PROFIT vs RISK RATING
1..100
100100
SMR RATING
1..100
9898
PRICE GROWTH RATING
1..100
5893
P/E GROWTH RATING
1..100
10025
SEASONALITY SCORE
1..100
9585

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

FRTX's Valuation (11) in the null industry is somewhat better than the same rating for LXRX (59) in the Biotechnology industry. This means that FRTX’s stock grew somewhat faster than LXRX’s over the last 12 months.

FRTX's Profit vs Risk Rating (100) in the null industry is in the same range as LXRX (100) in the Biotechnology industry. This means that FRTX’s stock grew similarly to LXRX’s over the last 12 months.

FRTX's SMR Rating (98) in the null industry is in the same range as LXRX (98) in the Biotechnology industry. This means that FRTX’s stock grew similarly to LXRX’s over the last 12 months.

FRTX's Price Growth Rating (58) in the null industry is somewhat better than the same rating for LXRX (93) in the Biotechnology industry. This means that FRTX’s stock grew somewhat faster than LXRX’s over the last 12 months.

LXRX's P/E Growth Rating (25) in the Biotechnology industry is significantly better than the same rating for FRTX (100) in the null industry. This means that LXRX’s stock grew significantly faster than FRTX’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
FRTXLXRX
RSI
ODDS (%)
Bearish Trend 2 days ago
90%
Bullish Trend 2 days ago
83%
Stochastic
ODDS (%)
Bearish Trend 2 days ago
87%
Bullish Trend 2 days ago
75%
Momentum
ODDS (%)
Bullish Trend 2 days ago
77%
Bullish Trend 2 days ago
74%
MACD
ODDS (%)
Bullish Trend 2 days ago
74%
Bullish Trend 2 days ago
90%
TrendWeek
ODDS (%)
Bullish Trend 2 days ago
71%
Bullish Trend 2 days ago
80%
TrendMonth
ODDS (%)
Bullish Trend 2 days ago
69%
Bearish Trend 2 days ago
89%
Advances
ODDS (%)
Bullish Trend 10 days ago
79%
Bullish Trend 10 days ago
81%
Declines
ODDS (%)
N/A
Bearish Trend 2 days ago
87%
BollingerBands
ODDS (%)
Bearish Trend 2 days ago
89%
N/A
Aroon
ODDS (%)
Bullish Trend 2 days ago
71%
Bearish Trend 2 days ago
90%
View a ticker or compare two or three
Ad is loading...
FRTX
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
LXRX
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
FSAVX57.46-0.13
-0.23%
Fidelity Select Automotive Port
HGHRX36.14-0.12
-0.33%
Hartford Healthcare R3
FIRCX8.65-0.03
-0.35%
Fidelity Advisor Intl Real Estate C
GAOSX20.85-0.09
-0.43%
JPMorgan Global Allocation I
FRISX100.05-0.56
-0.56%
Franklin Rising Dividends R6

FRTX and

Correlation & Price change

A.I.dvisor indicates that over the last year, FRTX has been loosely correlated with LXRX. These tickers have moved in lockstep 42% of the time. This A.I.-generated data suggests there is some statistical probability that if FRTX jumps, then LXRX could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To FRTX
1D Price
Change %
FRTX100%
N/A
LXRX - FRTX
42%
Loosely correlated
-4.64%
DRTS - FRTX
38%
Loosely correlated
+0.65%
SLNO - FRTX
37%
Loosely correlated
-0.58%
CALC - FRTX
37%
Loosely correlated
-1.07%
IMVT - FRTX
33%
Poorly correlated
+1.01%
More

LXRX and

Correlation & Price change

A.I.dvisor indicates that over the last year, LXRX has been loosely correlated with EPIX. These tickers have moved in lockstep 45% of the time. This A.I.-generated data suggests there is some statistical probability that if LXRX jumps, then EPIX could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To LXRX
1D Price
Change %
LXRX100%
-4.64%
EPIX - LXRX
45%
Loosely correlated
+0.61%
FRTX - LXRX
41%
Loosely correlated
N/A
NTLA - LXRX
37%
Loosely correlated
-1.87%
BEAM - LXRX
37%
Loosely correlated
-1.21%
SPRO - LXRX
37%
Loosely correlated
-3.27%
More